UBS Group
EIKN

UBS Group’s Eikon Therapeutics EIKN Stock Holding History

UBS Group’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
263,932
+164,524
+166% +$1.68M ﹤0.01% 4562
2026
Q1 		$1.05M Buy
+99,408
New +$1.33M ﹤0.01% 5517

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

UBS Group's EIKN Position: Q2 2026 in Review

UBS Group increased its Eikon Therapeutics (EIKN) stake by 166% in Q2 2026, buying an estimated $1.68M and bringing the position to 263,932 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4562.

UBS Group first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • UBS Group held 263,932 shares of Eikon Therapeutics worth $3.44M as of Q2 2026.
  • UBS Group bought 164,524 Eikon Therapeutics shares in Q2 2026, an estimated $1.68M.
  • Eikon Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4562 holding.
  • UBS Group first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.